Research programme: protein therapeutics - GNI/Merck

Drug Profile

Research programme: protein therapeutics - GNI/Merck

Latest Information Update: 19 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GNI; Organon; Shanghai Genomics
  • Developer GNI; Schering-Plough
  • Class Proteins
  • Mechanism of Action Steroid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Atherosclerosis; Cancer; Rheumatoid arthritis

Most Recent Events

  • 31 Dec 2009 No development reported - Preclinical for Atherosclerosis in China (unspecified route)
  • 31 Dec 2009 No development reported - Preclinical for Cancer in China (unspecified route)
  • 31 Dec 2009 No development reported - Preclinical for Rheumatoid arthritis in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top